{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:35:30Z","timestamp":1791858930295,"version":"4.3.4"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Recent advances in the management of transplant-associated thrombotic microangiopathy (TA-TMA) include the harmonization of diagnostic criteria and the identification of high-risk disease features. Individual hematologic and complement biomarkers show moderate specificity when used alone in the detection of TA-TMA in hematopoietic stem cell transplant (HSCT) recipients, but the identification of endothelial injury due to microangiopathic process can be enhanced using longitudinal monitoring of biomarkers and clinical features. An increase in the sC5b-9 level reflects terminal complement activation, a hallmark of TA-TMA pathogenesis that guides therapeutic interventions. In addition, distinguishing physiologic from pathologic complement activation is essential for timely diagnosis of the disease and selection of targeted interventions. Eculizumab therapy, a biomarker-guided C5 blocker, significantly improves clinical outcomes in severe TA-TMA; however, there is a lack of knowledge on how to select second-line complement inhibitors or combination therapies for cases with a suboptimal response to eculizumab. This article proposes practical approaches to increasing the specificity and attributability of TA-TMA diagnostic biomarkers by integrating clinically available supportive diagnostic tests and provides insights into potential biomarkers for currently available novel complement inhibitors. These findings help ensure timely diagnosis, prevent irreversible organ injury, and improve outcomes in HSCT recipients with TA-TMA.<\/jats:p>","DOI":"10.3389\/fmed.2025.1550365","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T05:27:13Z","timestamp":1746682033000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Translating biomarker insights into practice: a path forward in TA-TMA management"],"prefix":"10.3389","volume":"12","author":[{"given":"Sonata","family":"Jodele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Gavriilaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40164-021-00249-8","article-title":"Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy","volume":"10","author":"Gavriilaki","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","article-title":"Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic Microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific blood and marrow transplantation group, and Center for International Blood and Marrow Transplant Research","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/cpt.2966","article-title":"Adopting model-informed precision- dosing for Eculizumab in transplant associated-thrombotic Microangiopathy to gene therapies","volume":"114","author":"Jodele","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"392.e1","DOI":"10.1016\/j.jtct.2022.04.019","article-title":"Transplantation- associated thrombotic Microangiopathy risk stratification: is there a window of opportunity to improve outcomes?","volume":"28","author":"Jodele","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1002\/ajh.26872","article-title":"Reeling in complement in transplant-associated thrombotic microangiopathy: You're going to need a bigger boat","volume":"98","author":"Jodele","year":"2023","journal-title":"Am J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in thrombotic Microangiopathies: unraveling Ariadne's thread into the labyrinth of complement therapeutics","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s00134-024-07611-4","article-title":"Complement system activation: bridging physiology, pathophysiology, and therapy","volume":"50","author":"Azoulay","year":"2024","journal-title":"Intensive Care Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood.2023022526","article-title":"A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA","volume":"143","author":"Jodele","year":"2024","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1182\/bloodadvances.2021006523","article-title":"Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT","volume":"6","author":"Mizuno","year":"2022","journal-title":"Blood Adv"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood.2019004218","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1055\/s-0039-1692721","article-title":"Linking complement activation, coagulation, and neutrophils in transplant-associated thrombotic Microangiopathy","volume":"119","author":"Gavriilaki","year":"2019","journal-title":"Thromb Haemost"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.bbmt.2018.05.010","article-title":"Impact of thrombotic Microangiopathy on renal outcomes and survival after hematopoietic stem cell transplantation","volume":"24","author":"Postalcioglu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1016\/j.bbmt.2014.07.008","article-title":"Estimated versus measured glomerular filtration rate in children before hematopoietic cell transplantation","volume":"20","author":"Laskin","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"11028","DOI":"10.3390\/ijms252011028","article-title":"Soluble Urokinase-type plasminogen activator receptor (suPAR), growth differentiation Factor-15 (GDF-15), and soluble C5b-9 (sC5b-9) levels are significantly associated with endothelial injury indices in CAR-T cell recipients","volume":"25","author":"Gavriilaki","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/ndt\/gfad207","article-title":"2023 European pediatric hypertension guidelines: has anything changed?","volume":"39","author":"Baker-Smith","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.2215\/CJN.10630917","article-title":"Changes in glomerular filtration rate and impact on Long-term survival among adults after hematopoietic cell transplantation: a prospective cohort study","volume":"13","author":"Hingorani","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/bmt.2010.182","article-title":"Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT","volume":"46","author":"Laskin","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/bloodadvances.2020003455","article-title":"A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant","volume":"5","author":"Dandoy","year":"2021","journal-title":"Blood Adv"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.bbmt.2015.06.016","article-title":"Histologic features of intestinal thrombotic Microangiopathy in pediatric and young adult patients after hematopoietic stem cell transplantation","volume":"21","author":"El-Bietar","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00467-018-4178-x","article-title":"Haptoglobin degradation product as a novel serum biomarker for hematopoietic stem cell transplant- associated thrombotic microangiopathy","volume":"34","author":"Schuh","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/ajh.27186","article-title":"D-dimer and sinusoidal obstructive syndrome-novel poor prognostic features of thrombotic microangiopathy in children after hematopoietic cellular therapy in a single institution prospective cohort study","volume":"99","author":"Schoettler","year":"2024","journal-title":"Am J Hematol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"S175","DOI":"10.1016\/S2666-6367(21)00216-5","article-title":"Understanding the mechanisms of Eculizumab refractoriness in transplant associated thrombotic Microangiopathy","volume":"27","author":"Ibrahimova","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1076029619892684","DOI":"10.1177\/1076029619892684","article-title":"Von Willebrand factor as a predictor for transplant-associated thrombotic microangiopathy","volume":"26","author":"Xu","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/bjh.19506","article-title":"Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation-a secondary CIBMTR analysis","volume":"205","author":"Schoettler","year":"2024","journal-title":"Br J Haematol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"100020","DOI":"10.1016\/j.bvth.2024.100020","article-title":"Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202","volume":"1","author":"Newell","year":"2024","journal-title":"Blood Vessels Thrombosis Hemostasis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMc1700185","article-title":"ST2 and endothelial injury as a link between GVHD and Microangiopathy","volume":"376","author":"Rotz","year":"2017","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"685.e1","DOI":"10.1016\/j.jtct.2023.08.015","article-title":"Prospective clinical and biomarker validation of the American Society for Transplantation and Cellular Therapy Consensus Definition for transplantation-associated thrombotic Microangiopathy","volume":"29","author":"Ma","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1182\/blood.2021012860","article-title":"Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond","volume":"139","author":"Gavriilaki","year":"2022","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"601 e601","DOI":"10.1016\/j.jtct.2024.03.019","article-title":"Use of Eculizumab in pediatric patients with high-risk transplantation-associated thrombotic Microangiopathy: outcomes and risk factors associated with response and survival. A retrospective study on behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC)","volume":"30","author":"Benitez Carabante","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","article-title":"Variable Eculizumab clearance requires Pharmacodynamic monitoring to optimize therapy for thrombotic Microangiopathy after hematopoietic stem cell transplantation","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/bloodadvances.2020001515","article-title":"Interferon-complement loop in transplant-associated thrombotic microangiopathy","volume":"4","author":"Jodele","year":"2020","journal-title":"Blood Adv"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1182\/blood.2024025850","article-title":"Complement biosensors identify a classical pathway stimulus in complement-mediated thrombotic microangiopathy","volume":"144","author":"Cole","year":"2024","journal-title":"Blood"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/jth.12615","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome","volume":"12","author":"Cugno","year":"2014","journal-title":"J Thromb Haemost"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41409-024-02305-3","article-title":"Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience","volume":"59","author":"Castelli","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"336.e1","DOI":"10.1016\/j.jtct.2023.12.017","article-title":"Compassionate use Narsoplimab for severe refractory transplantation-associated thrombotic Microangiopathy in children","volume":"30","author":"Schoettler","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"714511","DOI":"10.3389\/fimmu.2021.714511","article-title":"Lectin pathway mediates complement activation by SARS-CoV-2 proteins","volume":"12","author":"Ali","year":"2021","journal-title":"Front Immunol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"152001","DOI":"10.1016\/j.imbio.2020.152001","article-title":"Endothelial injury and thrombotic microangiopathy in COVID-19: treatment with the lectin-pathway inhibitor narsoplimab","volume":"225","author":"Rambaldi","year":"2020","journal-title":"Immunobiology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"S378","DOI":"10.1016\/j.jtct.2025.01.583","article-title":"Narsoplimab for refractory transplantation-associated thrombotic Microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT) S378-S379","volume":"31","author":"Chumnumsiriwath","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12959-023-00464-9","article-title":"Narsoplimab for severe transplant-associated thrombotic microangiopathy","volume":"21","author":"Pandrowala","year":"2023","journal-title":"Thromb J"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"695037","DOI":"10.3389\/fimmu.2021.695037","article-title":"Early elevation of complement factor Ba is a predictive biomarker for transplant-associated thrombotic Microangiopathy","volume":"12","author":"Okamura","year":"2021","journal-title":"Front Immunol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e28070","DOI":"10.1002\/pbc.28070","article-title":"The alternative complement pathway activation product Ba as a marker for transplant-associated thrombotic microangiopathy","volume":"67","author":"Sartain","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1182\/bloodadvances.2019001242","article-title":"Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort","volume":"4","author":"Schoettler","year":"2020","journal-title":"Blood Adv."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.3390\/cimb46050288","article-title":"Genetic Susceptibility in Endothelial Injury Syndromes after Hematopoietic Cell Transplantation and Other Cellular Therapies: Climbing a Steep Hill","volume":"46","author":"Evangelidis","year":"2024","journal-title":"Curr Issues Mol Biol."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC","volume":"99","author":"de Fontbrune","year":"2015","journal-title":"Transplant."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/ejh.13127","article-title":"Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients","volume":"101","author":"Rudoni","year":"2018","journal-title":"Eur J Haematol."},{"key":"ref47","first-page":"601","article-title":"A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC)","volume":"30","author":"Ben\u00edtez Carabante","year":"2024","journal-title":"Transplant Cell Ther."},{"key":"ref48","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1200\/JCO.21.02389","article-title":"Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy. OMS721-TMA-001 Study Group Members","volume":"40","author":"Khaled","year":"2022","journal-title":"J Clin Oncol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1550365\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T05:27:15Z","timestamp":1746682035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1550365\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":48,"alternative-id":["10.3389\/fmed.2025.1550365"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1550365","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"article-number":"1550365"}}